"Das Vivantes Klinikum Neukölln ist ein Krankenhaus der Maximalversorgung und mit über 1.200 Betten eines der größten in Berlin.nsere Ärztinnen, Ärzte und Pflegkräfte sind gern für Sie da und versorgen Sie bei Erkrankungen oder Verletzungen in nahezu allen medizinischen Fachdisziplinen sowie rund um die Geburt mit Kompetenz, Erfahrung und Herz."

During the past decade, Vivantes Klinikum Neukölln conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 6 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vivantes Klinikum Neukölln" #1 sponsor was "University of Ulm" with 7 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "AIO-Studien-gGmbH" with 2 trials sponsored, "Charite University, Berlin, Germany" with 2 trials sponsored and "ExThera Medical Europe BV" with 2 trials sponsored. Other sponsors include 44 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vivantes Klinikum Neukölln" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Boston Scientific Corporation" with 2 trials as a collaborator, "Charite University, Berlin, Germany" with 2 trials as a collaborator, "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator and "ExThera Medical Corporation" with 2 trials as a collaborator. Other collaborators include 47 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "Vivantes Klinikum Neukölln" are "Acute Myeloid Leukemia" (8 trials), "Acute Lymphoblastic Leukemia" (2 trials), "Acute Myeloid Leukemia (AML)" (2 trials), "Atrial Fibrillation" (2 trials) and "COVID-19" (2 trials). Many other conditions were trialed in "Vivantes Klinikum Neukölln" in a lesser frequency.

Most popular intervention types in "Vivantes Klinikum Neukölln" are "Drug" (38 trials), "Device" (10 trials), "Procedure" (6 trials), "Other" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Cytarabine" (4 trials), "Daunorubicin" (4 trials), "BI 1015550" (2 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Vivantes Klinikum Neukölln" are 63 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Vivantes Klinikum Neukölln". undefined are not yet recruiting, 13 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Vivantes Klinikum Neukölln, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Vivantes Klinikum Neukölln, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 9 trials that are defined as “Not Applicable".